Cantargia is developing the antibody CAN04 for treatment of cancer. The ongoing phase I/IIa trial is primarily focused on treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. CAN04 is directed against interleukin-1 receptor accessory protein (IL1RAP) which is found on tumor cells from a wide range of cancer forms. IL1RAP is also found on inflammatory immune cells involved in cancer progression. Interim phase I data from 16 patients was presented at the ESMO conference in October 2018 and showed a good safety profile up to 6 mg/kg, a decrease in the biomarkers IL-6 and CRP and stable disease in 38 % of patients.